6533b837fe1ef96bd12a36cf
RESEARCH PRODUCT
“Bevacizumab (BEV),irinotecan (IRI), folinic acid (FA) and fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): the Southern Italy Cooperative Oncology Group (SICOG) experience”
P ComellaB MassiddaD NataleG FilippelliA FarrisG CondemiS TafutoG VessiaG. BarberisSergio Palmerisubject
Settore MED/06 - Oncologia Medicabevacizumabchemotherapymetastatic colorectal canceryear | journal | country | edition | language |
---|---|---|---|---|
2009-01-01 |